This matters because GLP-1 therapy involves metabolic, cardiovascular, and gastrointestinal considerations that deserve thorough screening
3) and an improvement in quality of life.40 Pending the results of cardiovascular safety studies in obesity (SURMOUNT MMO) and diabetes (SURPASS-CVOT), TZP has demonstrated in the SURMOUNT-1 trial a reduction in the predicted 10-year cardiovascular risk in patients with obesity and an initially moderate-to-high risk of cardiovascular disease.43 TZP treatment effectively reduces the apnoeahypopnoea index by up to 23 events per hour, as well as blood pressure, C-reactive protein, and symptoms related to poor sleep quality (as assessed by PROMIS Sleep scales), likely due to weight loss and improvement in adipocyte dysfunction.44 Moreover, TZP induces remission of histologically confirmed metabolic dysfunction-associated steatohepatitis (MASH) in a dose-dependent manner (4462% of cases, depending on the dose) and leads to improvement of at least one stage of liver fibrosis in 5155% of caseshigher than that observed with placebo45 (Fig
CMS requires providers to confirm the medication is used for weight reduction along with ongoing lifestyle changes, and that the individual met one of the following when treatment started: BMI 35 BMI 30 with conditions like HFpEF, uncontrolled hypertension, or CKD (stage 3a+) BMI 27 with prediabetes or established cardiovascular disease (e.g., prior MI, stroke, PAD) One important note: this coverage will operate outside of typical Part D plans, so the approval process will look different
Hellman, and Kelly Fennemore, MSN, ARNP, compound peptides for therapy to meet each patients unique healthcare needs
Results: Participants experienced significant weight loss
